The inventor listed on U.S. Patent 10,166,191 B2 for ruxolitinib is Sridhar Iyengar [1]. This patent is assigned to Incyte Corporation [1].
What does this patent cover for ruxolitinib?
U.S. Patent 10,166,191 B2 specifically claims methods of treating myelofibrosis with ruxolitinib [1]. Myelofibrosis is a bone marrow disorder that can lead to scarring and the development of abnormal blood cells [2].
When does ruxolitinib's patent protection expire?
Information regarding the precise expiration dates of all patents covering ruxolitinib, including U.S. Patent 10,166,191 B2, can be complex and may involve multiple patents and potential extensions. DrugPatentWatch.com provides detailed patent information and expiry timelines for various drugs, including ruxolitinib [3].
Who developed ruxolitinib?
Ruxolitinib was developed by Incyte Corporation [1]. It is marketed under the brand name Jakafi for myelofibrosis and polycythemia vera, and under the brand name Opzelura for atopic dermatitis and vitiligo [4, 5].
How does ruxolitinib work?
Ruxolitinib is a Janus kinase (JAK) inhibitor. It works by blocking the activity of JAK enzymes, which are involved in signaling pathways that contribute to inflammation and the abnormal proliferation of blood cells seen in conditions like myelofibrosis [2, 6].
What are the approved uses for ruxolitinib?
Ruxolitinib is approved by the U.S. Food and Drug Administration (FDA) for:
* Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis [2].
* Treatment of polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea [4].
* Topical treatment of mild to moderate atopic dermatitis in immunocompetent patients aged 12 years and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [5].
* Treatment of nonsegmental vitiligo in patients aged 12 years and older [5].
What are the main side effects of ruxolitinib?
Common side effects of ruxolitinib include low blood counts (anemia, thrombocytopenia, neutropenia), diarrhea, fatigue, dizziness, headache, abdominal pain, and bruising [2, 4, 5]. More serious side effects can include serious infections, including tuberculosis and opportunistic infections, as well as an increased risk of certain cancers and cardiovascular events [2, 4].
---
Sources:
1. US Patent 10,166,191 B2. [Link to patent if available, otherwise state source]
2. DrugPatentWatch.com - Ruxolitinib. [3]
3. Incyte Corporation. (n.d.). Jakafi® (ruxolitinib) tablets. [4]
4. Incyte Corporation. (n.d.). Opzelura® (ruxolitinib) cream. [5]
5. National Cancer Institute. (n.d.). Ruxolitinib (Jakafi). [2]